Background and purpose: Recent clinical trials and expert consensus guidelines have typically focused on the issue of systolic blood pressure (SBP) targets for reducing vascular risk. However, little is known about the relationship of the diastolic BP (DBP) level with vascular outcomes after a stroke. Methods: A multicenter trial dataset involving 3680 recent (<4 months) noncardioembolic stroke patients followed for 2 years was analyzed. Subjects were categorized per mean DBP level (mmHg) during follow-up: lowÀnormal (<70), normal (70 to <80), highÀnormal (80-89) and high (≥90). Pulse pressure (PP) was prespecified by three categories of <60, 60 to <70, and ≥70 mmHg. Independent associations of mean DBP level with major vascular events (MVEs) and ischaemic stroke were assessed. Results: Major vascular events occurred in 20.7% of the lowÀnormal, 15.1% of the normal, 16.9% of the highÀnormal and 19.2% of the high DBP groups, whilst stroke occurred in 9.9%, 6.8%, 8.5% and 10.8%, respectively. Compared with the normal DBP group, risk of MVEs was higher in the lowÀnormal DBP group (adjusted hazard ratio 1.33; 95% confidence interval 1.04-1.71). Amongst those with SBP 120 to <140 mmHg, risk of MVEs (1.89; 1.13-3.15) and stroke (2.87; 1.48-5.53) was higher in subjects with PP ≥70 (mean DBP 62.4 AE 3.8) than those with the lowest PP (mean DBP 78.0 AE 5.9) whilst, amongst those with SBP <120 mmHg, PP 60 to <70 (mean DBP 52.7 AE 2.5) was associated with increased risk of stroke (5.85; 1.25-27.5). Conclusion: Diastolic BP levels in the lowÀnormal range, particularly accompanied by an increased PP of >60, confer increased risk of MVEs and stroke amongst patients after recent non-cardioembolic stroke.
Introduction
Hypertension is the most common and leading risk factor for stroke by~60% in men and women of all ages [1] . Several published studies have looked at the association of blood pressure (BP) with the future risk of vascular events, but reports regarding this relationship in people with a history of stroke are much fewer and they are even fewer amongst those with a recent ischaemic stroke [2, 3] . These limited data (one randomized trial and a couple of observational studies) have primarily focused on systolic BP (SBP) level and have suggested a trend towards benefit for SBP <130 mmHg in patients with lacunar stroke [4] or a Jshaped association for SBP with harm at <120 mmHg for all non-cardioembolic stroke types [2, 3] .
With regard to diastolic BP (DBP), a post hoc analysis of >22 000 hypertensive patients with coronary artery disease showed that lower DBP (<70-80 mmHg) was associated with an increased risk of all-cause death and myocardial infarction probably due to compromised coronary artery perfusion, thereby causing cardiac ischaemia [5] . However, little is known about whether such a J-shaped relationship exists for DBP and recurrent vascular risk after a stroke.
Pending the conduct of dedicated clinical trials aimed at addressing the question of the optimal BP target for secondary prevention after stroke, more information about the possible nature of the relationship of achieved DBP and post-stroke vascular risk could be insightful. Therefore, the objective of this study was to evaluate the relationship between DBP and future major vascular events (MVEs) amongst patients following a recent stroke.
Methods Study subjects and database
This is a post hoc analysis of data from the Vitamin Intervention for Stroke Prevention (VISP) trial [6] . The VISP study was a multinational, double blind, randomized controlled clinical trial performed at 56 centers across the USA, Canada and Scotland. The study enrolled 3680 subjects aged ≥35 years to determine whether high doses of multivitamins (folic acid, pyridoxine and cobalamin) given to lower total homocysteine levels would reduce the risk of recurrent stroke and MVEs in subjects with a non-cardioembolic stroke within 120 days [6] . Demographic, clinical and laboratory data, including BP recordings, were collected at baseline, with subsequent clinical and laboratory information obtained at follow-up visits of 1, 6, 12, 18 and 24 months [6] . BP was measured twice at 5 min interval, and the measurements were averaged. For each patient, the presence of hypertension, diabetes and body mass index, which was calculated as weight in kilograms divided by square of height in meters, were retrieved at the baseline visit. Secondary prevention medications including antihypertensive, antithrombotic (antiplatelet/anticoagulation) and lipid-modifying therapy (statins mostly) were further reviewed; all of them were collected at every 6-month interval follow-up visit. The trial was approved by the ethics committee or institutional review board at each national or local site, and all participants provided written informed consent before enrolment [6] .
Vascular end-points
The primary outcome was a composite of stroke, coronary heart disease (CHD) including myocardial infarction, coronary revascularization, cardiac resuscitation and fatal CHD, or vascular death defined as MVEs. Secondary outcome was ischaemic stroke. Each adjudicated end-point in VISP was verified through consensus of a review committee [6] .
Statistical analysis
On the basis of expert consensus guideline classification of DBP, normal (<80 mmHg) prehypertension (80-89 mmHg), stage 1 hypertension (90-99 mmHg) and stage 2 hypertension (>100 mmHg) [7] , study participants were categorized into four groups according to their mean DBP level during the follow-up: lowÀnormal (<70 mmHg), normal (70 to <80 mmHg), normal to highÀnormal (80-89 mmHg) and high (≥90 mmHg). The group with normal DBP was the referent group. Mean follow-up DBP from the baseline to final visit was calculated for each subject. Given that an increased pulse pressure (PP) yielding low DBP reflects increased stiffness in the aorta and other large arteries [8] , and the J-shaped relationship between DBP and cardiac outcomes [5] , the relationship of PP (by mean SBP -mean DBP) and mean DBP with vascular outcomes was also evaluated. Since low DBP and a high PP of >60 mmHg were reported to be risk factors for incident CHD amongst participants with an SBP of ≥120 mmHg [9] , the PP was prespecified by three categories of <60, 60 to <70 and ≥70 mmHg. The group with the lowest PP was the referent group. Subjects not having outcome events were censored at last follow-up examination, or last visit until he/she died or experienced an outcome. Independent associations of SBP by ordinal category (<120; 120 to <140; 140-159; and ≥160 mmHg) [7] with vascular outcomes were further analyzed with the second SBP level as the referent group. A total of 152 patients had few follow-up BP data since randomization; 109 had one follow-up BP data and 43 had no follow-up. For the latter patients, baseline BP was used as the proxy.
Comparisons across the BP groups and the PP groups were examined using a one-way analysis of variance, followed by the Dunnett test for multiple comparisons, for continuous variables and the chisquared test for categorical variables. Multivariate analyses to estimate the risk of outcome events at 2 years were performed using Cox regression models including the following variables: age, sex, race, body mass index, Mini-Mental State Examination score, low-density lipoprotein cholesterol, mean SBP, diabetes mellitus, qualifying stroke severity, history of stroke (before qualifying stroke), history of CHD, history of heart failure, history of carotid endarterectomy, history of alcohol use, lipid modifier use and antithrombotic use (all P < 0.10, model I); and model I plus antihypertensive use (model II). Results are given by hazard ratio (HR) and its 95% confidence interval (CI). The interaction between mean SBP level and each mean DBP category in predicting the risk of vascular outcome event was assessed by including the appropriate interaction terms in the model. The above analyses were conducted using IBM SPSS Version 22.0 (IBM Corp., Armonk, NY, USA) and survival curves were fitted by the log-rank tests using MedCalc software version 5.0 (Mariakerke, Belgium). A probability value of <0.05 was considered statistically significant.
Results

Subject characteristics by mean DBP categories
Mean baseline SBP and DBP of the study subjects were 140.5 AE 15.5 mmHg and 77.8 AE 8.2 mmHg, respectively. Distributions of subjects by 10 mmHg strata of mean DBP are shown in Fig. S1 . Table 1 presents baseline demographic and clinical characteristics of 3680 participants in the three groups of mean DBP. Compared with the lowÀnormal DBP group, the high DBP group was younger, had higher levels of body mass index, mean SBP, total cholesterol and low-density lipoprotein cholesterol, higher of men, non-white, hypertension, antihypertensive medication and history of alcohol use, whereas rates of diabetes and lipid modifier use and histories of CHD, heart failure and carotid endarterectomy were lower. Additionally, qualifying stroke severity was more likely to be greater in the lowÀnormal group. Table 2 displays various BP parameters (i.e. mean baseline, mean follow-up and mean change) by mean DBP categories. Mean baseline and follow-up SBP/DBP as well as mean SBP/DBP change were highest in the high DBP group. Specifically, baseline DBP was 65.7 AE 7.3 mmHg in the 
Associations of mean DBP level and vascular outcomes
During 2 years of follow-up, a total of 619 (16.8%) MVEs and 300 (8.2%) strokes were observed. The occurrence of MVEs and stroke was higher in the lowÀnormal DBP group (20.7% and 9.9%, respectively) and high DBP group (19.2% and 10.8%, respectively). The results of the unadjusted and multivariable adjusted associations of mean DBP with vascular outcomes are given in Table 3 . The occurrence of MVEs was highest in the lowÀnormal DBP group (HR 1.46; 95% CI 1.16-1.82; P = 0.001), followed by the high DBP group (HR 1.40; 95% CI 1.05-1.88; P = 0.023). Compared with the normal DBP group, the occurrence of recurrent stroke was greatest in the high DBP group (HR 1.75; 95% CI 1.18-2.61; P = 0.006), followed by the lowÀnormal DBP group (HR 1.52; 95% CI 1.09-2.12; P = 0.013). In multivariable analyses, compared with the normal DBP group, risk of MVEs was significantly higher in the lowÀnor-mal DBP group (HR 1.33; 95% CI 1.04-1.71; P = 0.025) and this association remained constant after further adjustment for antihypertensive medication (HR 1.33; 95% CI 1.04-1.71; P = 0.026). The high DBP group showed a trend towards higher risk of MVEs (models I and II).
For the secondary outcome, compared with the normal DBP group, a significant association of lowÀnormal DBP or high DBP with risk of recurrent stroke disappeared after multivariable adjustment (models I and II). Figure 1 displays the Kaplan-Meier curves for the end-points of MVEs amongst subjects over 2 years after a recent non-cardioembolic stroke by DBP categories, which revealed a higher risk in the lowÀnormal DBP group (P = 0.0045 by log-rank test). Figures S2 and S3 depict percentages of MVEs and recurrent stroke, respectively, by mean DBP category that reveal near-similar J-curve patterns to the relationships with vascular outcomes. The adjusted HRs of covariates included in the multivariable model are given in Table S1 . Lipid modifier use was linked to a lesser risk of both MVEs and stroke, whilst diabetes was a potent predictor of both vascular outcomes. History of CHD and history of heart failure were predictors of MVEs. Table S2 provides the unadjusted and adjusted HRs for vascular outcomes by mean SBP categories. For MVEs, compared with the SBP level 120 to <140 mmHg, SBP level ≥160 mmHg had a greater risk of MVEs (HR 1.54) but SBP level <120 mmHg showed a trend towards higher risk after multivariable adjustment. For stroke, compared with the SBP level 120 to <140 mmHg, both SBP level <120 mmHg and SBP level ≥160 mmHg were associated with increased risk of ischaemic stroke after multivariable adjustment (HR 1.71 and HR 1.57, respectively). The interaction effect between variable and mean DBP categories on the risk of MVEs is shown in Table S3 . There was a significant interaction of age with the MVEs (i.e. more events in the lowÀnormal DBP group; P = 0.044), but the interaction effect between mean SBP level and mean DBP category was not significant.
Associations of PP with vascular outcomes by mean SBP categories
Results of the adjusted associations of PP with vascular outcomes stratified by mean SBP categories are shown in Table 4 . The SBP categories were compressed to preserve power (<120; 120 to <140; and ≥140 mmHg) due to no stroke events in patients with an SBP ≥160 mmHg and a PP <60. Compared with the PP <60 group, the mean DBP levels of subjects with the highest PP (>70 mmHg) were significantly lower in each of the SBP categories (P < 0.001 for all). Amongst those with an SBP 120 to <140 mmHg, compared with the lowest PP group, a low mean DBP and a PP ≥70 were linked to an increased risk of MVEs (HR 1.89; 95% CI 1.13-3.15; P = 0.016). Consistent with this, the association of low mean DBP and the highest PP with stroke was also evident amongst those with an SBP of 120 to <140 mmHg (HR 2.87; 95% CI 1.48-5.53; P = 0.002). Amongst those with an SBP <120 mmHg, a PP of 60 to <70 mmHg (mean DBP 52.7 AE 2.5 mmHg) showed a pattern towards higher risk of MVEs (HR 3.68; 95% CI 0.84-16.15) and was associated with increased risk of stroke (HR 5.85; 95% CI 1.25-27.5; P = 0.025). However, these associations were not observed in those with an SBP ≥140 mmHg. The Kaplan-Meier curves for the vascular end-points in each of the mean SBP categories over the 2-year follow-up period depict higher probabilities of MVEs and stroke in subjects with an SBP of 120 to <140 mmHg (P = 0.0001 for all) and a greater probability of stroke in those with an SBP of <120 mmHg (P = 0.0111, Fig. 2 ).
Discussion
This is the first study as far as the authors are aware that sought to examine the independent association of DBP with vascular outcomes after a recent stroke over a 2-year follow-up period. Compared with the normal DBP group, the risk of MVEs was significantly higher by over 30% for the lowÀnormal DBP group (<70 mmHg) than the normal DBP group after multivariable adjustment. Since the lowÀnormal DBP group had higher comorbidities of diabetes, CHD, heart failure and carotid artery disease, and had more severe qualifying strokes, it is conceivable that the relationship between lowÀnormal DBP and adverse vascular outcomes after stroke might reflect underlying poor health condition per se that predisposes to negative vascular outcomes. However, our finding was independent of mean SBP levels, vascular comorbidities, treatment strategy including antithrombotic therapies, lipid modifiers and antihypertensive medications. Also, mean SBP showed no interaction with mean DBP. High DBP level (>90 mmHg) was linked to an increased risk of MVEs, but this association was attenuated after adjusting for covariates. For the secondary outcome of stroke alone, compared with the normal DBP group, lowÀnormal DBP showed a pattern of greater risk of recurrent stroke after multivariable adjustment.
With regard to the PP, the risk of MVEs was significantly greater by approximately 2-fold for subjects with a PP ≥70 (mean DBP 62.4 AE 3.8 mmHg) than those with the lowest PP (mean DBP 78.0 AE 5.9 mmHg) amongst those with an SBP of 120 to <140 mmHg, CHD, coronary heart disease; CI, confidence interval; DBP, diastolic blood pressure; HR, hazard ratio.*P < 0.01; **P < 0.05; a adjusted for age, sex, ethnicity, body mass index, Mini-Mental State Examination score, low-density lipoprotein cholesterol, mean systolic BP, diabetes mellitus, qualifying stroke severity, history of stroke (before qualifying stroke), history of CHD, history of heart failure, history of carotid endarterectomy, history of alcohol use, lipid modifier use and antithrombotic use; b adjusted for model I plus antihypertensive use.
which is a similar pattern to findings from a recent study [9] that a low DBP of <70 mmHg was associated with subclinical myocardial damage and CHD events in the Atherosclerosis Risk in Communities cohort comprising >11 000 adults. The risk of coronary events in patients with CHD is more related to lower DBP than lower SBP, since low DBP could compromise coronary perfusion, yielding cardiac ischaemia [5] . Given that a history of CHD was a predictor of MVEs in our study, subjects with low DBP and a history of CHD would have been susceptible to MVEs. However, the finding that occurrence of incident stroke was also significantly higher (HR 2.87) in that category (SBP 120 to <140 mmHg) conflicts with the result [9] that low DBP was not associated with incident stroke. Factors that may contribute to the conflicting findings of our sub-analysis of the VISP trial [6] versus the other study [9] include study population (stroke survivors versus healthy community adults), mean age (66 years versus 57 years), and different rates of male sex (63% vs. 43%). In this study, mean SBP <120 mmHg was associated with higher risk of stroke (HR 1.71 in Table S2 ), which is a roughly similar pattern to the finding (HR 1.29) from a previous study [3] . Of note, that association was evident in subjects whose PP was over 60 with low mean DBP of <60 mmHg, the finding of which probably reflects more advanced vascular morbidity in those with a PP ≥60 vs. <60. However, since the sample size was very small (n = 5) and the CI was wide in subjects with an SBP <120 mmHg with a PP >60, our finding needs to be validated in a much larger study.
Contrary to the finding amongst subjects with an SBP <140 mmHg, elevated PP was not a powerful determinant of the risk of MVEs or stroke in those with an SBP ≥140 mmHg. This null finding in those with an SBP ≥140 mmHg may be because all the mean DBP levels were around 80 mmHg or more, irrespective of PP category. An increase in SBP might have outweighed a decrease in DBP.
Also, no association of high DBP (>90 mmHg) with the risk of MVEs or stroke might have been due to the relatively small number of patients with DBP >90 mmHg (n = 239, 6.5%), particularly in those with a DBP of >100 mmHg (n = 14, 0.4%), which is shown in Fig. S1 . Taking the aforementioned findings into account, our findings suggest that low DBP (versus high DBP) along with an increased PP may confer higher risk of recurrent vascular events amongst patients following a non-cardioembolic stroke.
Across mean DBP categories, there was a significant interaction between age and mean DBP on outcome in this study such that older age was associated with more MVEs in the lowÀnormal DBP group. Given that the lowÀnormal DBP group was older and more likely to be lean across the DBP categories, this finding may concur with a previous study which implied that lean stroke patients may be more prone to risk of MVEs [10] in an 'obesity paradox' [11] .
This study has some limitations. This is a post hoc exploratory analysis, and thus our findings showing associations of low DBP and increased PP with vascular outcomes do not prove that low DBP <70 mmHg and Figure 2 Kaplan-Meier curves for the end-points of major vascular events (a) and stroke (b) amongst subjects with an SBP <120 mmHg, an SBP of 120 to <140 mmHg and an SBP ≥140 mmHg over 2 years after a recent non-cardioembolic stroke based on pulse pressure (<60, 60 to <70 and ≥70). SBP, systolic blood pressure. [Colour figure can be viewed at wileyonlinelibrary.com].
increased PP will definitely lead to adverse vascular outcomes. These results should be seen simply as hypothesis generating. Moreover, all study participants experienced non-cardioembolic strokes thereby limiting generalizability to all stroke types (i.e. including cardioembolic and hemorrhagic strokes). There was a relatively modest number of subjects with DBP >90 mmHg, particularly those with DBP >100 mmHg (0.4%), which might have influenced the statistical power for observing vascular events in the category of high DBP. Also the very small sample size (n = 5) in subjects with an SBP <120 mmHg with a PP >60 jeopardizes the precision of estimates for vascular events. Finally, no adjustment could be made for beta-blockers and some calcium antagonists (i.e. diltiazem, verapamil) that may aggravate the diastolic hypotension by widening the PP [8] because there was no specific information about these particular drugs in the VISP database which might have otherwise influenced the current results.
In conclusion, amongst patients with a recent noncardioembolic stroke, low DBP (<70 mmHg), particularly with an increased PP of >60-70, was linked to a significantly greater risk of MVEs and stroke over a 2-year follow-up period. However, a high DBP level by itself did not have a significant impact on the risk of vascular events over the same time period, which underscores the stronger impact of high SBP on vascular risk. This study suggests that, amongst patients being treated with antihypertensive therapy for secondary stroke prevention, closer surveillance may need to be paid not only to SBP but also to achieved DBP and PP to avoid the occurrence of untoward vascular events. Our findings need to be validated through prospective studies with higher numbers of patients and minimization of potential confounders including underlying cerebrovascular status. Figure S1 . The proportions of patients by 10 mmHg strata of mean diastolic blood pressure. Figure S2 . Percentage of major vascular events by mean diastolic blood pressure categories amongst subjects with a recent non-cardioembolic stroke. CHD, coronary heart disease. Figure S3 . Percentage of recurrent stroke by mean diastolic blood pressure categories amongst subjects with a recent non-cardioembolic stroke. Table S1 . Multivariable adjusted hazard ratios (HRs) of covariates included in the Cox models of vascular outcomes by mean diastolic blood pressure categories. Table S2 . Hazard ratios (HRs) for vascular outcomes by mean SBP categories at 2 years. Table S3 . Interaction effect between variables and mean DBP categories.
